Intravitreal Bevacizumab for Diabetic Retinopathy
Background: to evaluate the 3-month efficacy of a single dose of intravitreal bevacizumab on the progression of severe non proliferative diabetic retinopathy, proliferative diabetic retinopathy and active photocoagulated diabetic proliferative by evaluation of ischemic areas and regression of retinal and disc neovasculrization.
Methods: 40 patients were enrolled in a prospective, interventional study. Patients were treated with intravitreal bevacizumab 0.1ml (0.25mg). We evaluated visual acuity, neovascularization leakage points, capillary closure ischemic areas and macular edema by clinical examination and fluorescein angiography. A clinical examination was performed at baseline and days 1,14 and 30. Active leakage points were measured by fluorescein angiography at 30 days.
|Severe Nonproliferative Proliferative Diabetic Retinopathy Active Photocoagulated Diabetic Retinopathy||Drug: intravitreal bevacizumab||Phase 2 Phase 3|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Efficacy of Intravitreal Bevacizumab for Severe Nonproliferative and Proliferative Diabetic Retinopathy.|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00600262
|Elizabeth Reyna Castelan|
|Mexico City, Mexico, 04030|
|Principal Investigator:||Elizabeth Reyna-Castelan, MD||Asociación para evitar la ceguera en Mexico|
|Study Chair:||Mariana Martinez-Castellanos, MD||Asociación para Evitar la Ceguera en México|